Homology Medicines (FIXX) said on Tuesday a peer-reviewed publication showed its adeno-associated viral vectors (AAVHSCs) crossed the blood-brain-barrier and blood-nerve-barrier in non-human primates, highlighting their potential to deliver gene therapy for central and peripheral nervous system disorders.

“We have observed that small sequence changes among our family of AAVHSCs are associated with differences in their ability to target disease-relevant tissues. We continue to characterize these properties and the potential of AAVHSCs as vehicles for therapeutic delivery,” said Albert Seymour, chief scientific officer of Homology.